

2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020)

Thursday, 5 March 2020

Israel Hall	
08:00-08:30	Registration & Gathering
Opening Ceremony	
08:30-08:50	08:30-08:40: Welcome Greetings Moshe Mittelman (Israel); Stephen Nimer (USA) 08:40-08:50: The History of MDS Moshe Mittelman (Israel)
Session 1: Genetics, Biology and Epidemiology Chairs: Galia Stemer (Israel); David Steensma (USA)	
08:50-10:20	08:50-09:10: Genetics of MDS Rafael Bejar (USA) 09:10-09:30: MDS and Clonal Hematopoiesis David Steensma (USA) 09:30-09:50: ICUS and CCUS: non-MDS, pre-MDS or early MDS? Luca Malcovati (Italy) 09:50-10:00: Etiology and Epidemiology Drorit Merkel (Israel) 10:00-10:20: The Role of Stem Cells Ghulam Mufti (UK)
Coffee Break & Visit Exhibition	
Session 2: Pathogenesis and Diagnosis Chairs: Kalman Filanovsky (Israel); Theo de Witte (The Netherlands)	
11:00-13:00	11:00-11:20: Innate Immunity in MDS Pathogenesis Alan List (USA) 11:20-11:40: AML post MDS Yishai Ofran (Israel) <i>Supported by AbbVie</i> 11:40-12:00: Lessons from the EUMDS Registry Theo de Witte (The Netherlands) MDS – Non-Routine Diagnosis: 12:00-12:10: MicroRNA Signature in Myelodysplastic Syndrome Inga Mandac (Croatia) 12:10-12:20: Can We Diagnose MDS Without a BM Examination? Howard S. Oster (Israel) 12:20-13:00: Patient Discussion 1 Panel: Alan List (USA); Yishai Ofran (Israel); Ghulam Mufti (UK); Rafael Bejar (USA) Presenters: Marin Ellis (Israel); Drorit Merkel (Israel); Merav Barzilai (Israel)

	Israel Hall
13:00-13:30	Lunch Break & Visit Exhibition
	Satellite symposium supported by Novartis: Iron chelation and targeted therapy in MDS: Shifting the treatment paradigm
13:30-14:30	<p>13:30-13:45 Welcome and Introductions Moshe Mittelman - Chair (Israel) Are current therapies doing enough to meet the needs of patients with MDS? Panel discussion</p> <p>13:45-14:00 Rethinking treatment selection for patients with low-risk MDS Emanuele Angelucci (Italy)</p> <p>14:00-14:15 Moving towards a targeted approach for patients with MDS Uwe Platzbecker (Germany)</p> <p>14:15-14:30 Paving the way for novel therapeutic opportunities in MDS Q&A and Panel discussion Meeting close Moshe Mittelman (Israel)</p>
	Session 3: Clinical MDS (I) Supported by Fibrogen and Neopharm Israel Chairs: Hanna Tamari (Israel); Peter Greenberg (USA)
14:30-15:50	<p>14:30-14:50: Genetic Predisposition to MDS Akiko Shimamura (USA)</p> <p>14:50-15:10: Molecular and Clinical Classifications of MDS Peter Greenberg (USA)</p> <p>15:10-15:30: Splicing Factor Mutant Myelodysplastic Syndromes Luca Malcovati (Italy)</p> <p>15:30-15:50: Precision Medicine in 2020 Stephen Nimer (USA)</p>
15:50-16:30	Coffee Break & Visit Exhibition
	Session 4: Clinical MDS (II) Chairs: Maya Koren-Michowitz (Israel); Rena Buckstein (Canada)
16:30-18:00	<p>16:30-16:50: The Impact of Comorbidities and Infections in the Course and Prognosis of MDS Argiris Symeonidis (Greece)</p> <p>16:50-17:10: Optimizing Transfusion Support in MDS. Is What We Are Doing What Patients Want? Rena Buckstein (Canada)</p> <p>17:10-18:00: Patient Discussion 2 Panel: Akiko Shimamura (USA); Peter Greenberg (USA); Argiris Symeonidis (Greece); Rena Buckstein (Canada) Presenters: Maya Zlotnick (Israel); Mika Geva (Israel); Efrat Yaara ArzyHabar (Israel)</p>
	Satellite symposium supported by Celgene. A Bristol-Myers Squibb Company: Ineffective erythropoiesis in MDS: Targets for treatment in the new decade
18:00-19:00	<p>18:00 – 18:05 Welcome and introduction Moshe Mittelman - Chair (Israel)</p> <p>18:05 – 18:25 Ineffective erythropoiesis in MDS – what do we know? Moshe Mittelman (Israel)</p> <p>18:25 – 18:55 Novel treatment targets: investigating key players in the regulation of erythropoiesis Valeria Santini (Italy)</p> <p>18:55 – 19:00 Closing remarks Moshe Mittelman (Israel)</p>
19:00-20:00	Evening Reception supported by BMS (Exhibition)

2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020)

Friday, 6 March 2020

Israel Hall	
08:30-10:30	<p>Session 5: Treatment of MDS (I) <i>Supported by Gamida Cell Boston</i> Chairs: Ilana Hellman (Israel); Valeria Santini (Italy)</p> <p>08:30-09:00: Treatment of Anemia and Thrombocytopenia Uwe Platzbecker (Germany)</p> <p>09:00-09:20: Lenalidomide and Immune Suppressive Treatment Valeria Santini (Italy)</p> <p>09:20-09:40: Stem Cell Transplant Theo de Witte (The Netherlands)</p> <p>09:40-10:30: Patient Discussion 3 Panel: Uwe Platzbecker (Germany); Valeria Santini (Italy); Theo de Witte (The Netherlands); Jacob Rowe (Israel) Presenters: Nicolas Bonadies (Switzerland); Galia Stemer (Israel); May Basood (Israel)</p>
10:30-11:00	Coffee Break & Visit Exhibition
11:00-13:00	<p>Session 6: Treatment of MDS (II) <i>Supported by Takeda Oncology</i> Chairs: Yishai Ofran (Israel); Pierre Fenaux (France)</p> <p>11:00-11:20: Hypomethylating Agents Pierre Fenaux (France)</p> <p>11:20-11:40: Beyond HMA (I) – Combinations of Drugs Mikkael Sekeres (USA)</p> <p>11:40-12:00: Beyond HMA (II) – Novel Agents Lewis Silverman (USA)</p> <p>12:00-12:20: What is in the pipeline? Guillermo Garcia-Manero (USA)</p> <p>12:20-13:00: Patient discussion 4 Panel: Mikkael Sekeres (USA); Lewis Silverman (USA); Guillermo Garcia-Manero (USA); Ofir Wallach (Israel) Presenters: Rotem keidar (Israel); Kalman Filanovski (Israel); Moshe Mittelman (Israel)</p>
13:00-13:10	<p>Farewell:</p> <p>Closing Remarks Drorit Merkel (Israel); Stephen Nimer (USA)</p> <p>2nd Latin American MDS Symposium 2020 in Uruguay Marcelo Iastrebner (Uruguay)</p> <p>MDS 2021, Toronto Rena Buckstein (Canada)</p>